NPS Pharmaceuticals 8-K 2006
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 2, 2006
Date of Report (Date of earliest event reported)
NPS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
383 Colorow Drive
Salt Lake City, Utah 84108
(Address of principal executive offices)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On May 2, 2006, NPS Pharmaceuticals issued a press release announcing that the lead compound in development by partner GlaxoSmithKline successfully completed a proof of concept trial and would expand the development of the compound. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
99.1 Press Release issued by NPS Pharmaceuticals on May 2, 2006.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.